Chengdu Kanghong Pharmaceuticals GroupCo., Ltd.

LUMITIN

The mark consists of the words LUMITIN.;Medicines for humans used for the treatment of choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-relatedmacular degeneration, retinal vein occlusion, neoplastic disease and cancer, angiogenesis disease; Pharmaceutical preparations for the treatment of diabetes, cardiovascular disease and disorder, neoplastic disease and disorder, cancer, disease and disorder of immune system, angiogenesis disease and disorder, ophthalmic diseases and disorder, mental disease and disorder, aged-related macular degeneration; Injectable preparations for medical use, namely, for the treatment of oculopathy, choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-related macular degeneration, retinal vein occlusion, neoplastic disease, angiogenesis disease and cancer; Aqueous formula, namely, water-based pharmaceutical preparations for the treatment of cardiovascular disease and disorder, neoplastic disease and disorder, disease and disorder of immune system, ophthalmic diseases and disorder, inflammation; Biochemical drugs and preparations for medical use, namely, for the prevention, treatment and alleviation of angiogenesis disease, oculopathy, neoplastic disease, cancer, all of the foregoing being available by prescription only;Color is not claimed as a feature of the mark.;The wording LUMITIN has no meaning in a foreign language.;